Selected article for: "fatigue headache cough and headache sore throat cough include"

Author: Pirzada, Ashar; Mokhtar, Ahmed T.; Moeller, Andrew D.
Title: COVID-19 and myocarditis: What do we know so far?
  • Cord-id: wq89wtwf
  • Document date: 2020_5_28
  • ID: wq89wtwf
    Snippet: COVID-19 has been declared a global pandemic by the World Health Organization and is responsible for hundreds of thousands of deaths worldwide. COVID-19 is caused by SARS-CoV-2, and common clinical symptoms include fever, cough, sore throat, headache, and fatigue. Myocardial injury is relatively common in COVID-19, accounting for 7-23% of cases, and is associated with a higher morbidity and mortality. There is a discrepancy in the literature about myocarditis as the etiology of myocardial injury
    Document: COVID-19 has been declared a global pandemic by the World Health Organization and is responsible for hundreds of thousands of deaths worldwide. COVID-19 is caused by SARS-CoV-2, and common clinical symptoms include fever, cough, sore throat, headache, and fatigue. Myocardial injury is relatively common in COVID-19, accounting for 7-23% of cases, and is associated with a higher morbidity and mortality. There is a discrepancy in the literature about myocarditis as the etiology of myocardial injury in COVID-19; although many anecdotal reports of myocarditis have been noted, there are only a handful of case reports in the literature about myocarditis related to COVID-19. This review summarizes the most up-to-date literature around the association between COVID-19 and myocarditis and gives clinicians a practical framework about the clinical manifestations, diagnostic tools and treatment options currently available. Importantly, this review will heighten suspicion for myocarditis as an etiology of myocardial injury in COVID-19 patients, therefore improving clinical outcomes and encouraging shared clinical decision-making. This will also open the door for further research to build around this review. Emergent treatment options for COVID-19 are in clinical trials and may be of benefit to COVID-19 patients with myocarditis in addition to current guideline-based recommendations.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute myocardial infarction: 1, 2, 3, 4, 5, 6
    • abdominal pain and acute onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • abdominal pain and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • abdominal pain and adenovirus enterovirus: 1, 2
    • abdominal pain and lopinavir ritonavir: 1, 2, 3, 4
    • abdominal pain and low prevalence: 1, 2, 3, 4
    • abdominal pain and lung injury: 1, 2, 3, 4, 5
    • abdominal pain and lv dysfunction: 1
    • actual cause and acute respiratory: 1, 2
    • acute coronary syndrome and lopinavir ritonavir: 1, 2
    • acute coronary syndrome and low prevalence: 1, 2
    • acute coronary syndrome and lung injury: 1
    • acute coronary syndrome and lung injury ards: 1
    • acute coronary syndrome and lv dysfunction: 1, 2
    • acute coronary syndrome and lv function: 1
    • acute myocardial infarction and lung injury: 1, 2, 3
    • acute myocardial infarction and lung injury ards: 1
    • acute myocardial infarction and lv dysfunction: 1